News & Updates

The risk of developing acute kidney injury (AKI) is significantly higher in critically ill patients with influenza A than those with COVID-19, a study by researchers at the University of Hong Kong (HKU) has found.

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.

Valve surgery or percutaneous mechanical aspiration, in combination with medical therapy, fall short of providing survival benefits to patients with isolated tricuspid valve infective endocarditis, results of a study have shown. However, addiction medicine consultation appears to be protective against the risk of death at 1 year in this population.

In Singapore, influenza and pneumococcal vaccination coverage remains stubbornly low. Results of two separate analysis of a cross-sectional survey shed light on this concerning trend, highlighting the roles of vaccine knowledge and attitude, healthcare professionals, and social support in influencing vaccination decisions.

COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.

Adding sodium–glucose co-transporter-2 (SGLT2) inhibitors to usual care in the treatment of hospitalized patients with COVID-19 does not necessarily lead to improved survival, according to the results of a meta-analysis.

In a nationwide French cohort study, myocarditis attributed to COVID-19 mRNA vaccination causes fewer cardiovascular (CV) events at 18 months of follow-up than that attributed to SARS-CoV-2 infection or myocarditis of conventional aetiologies.